Elizabeth J. Shpall

Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice.

High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?

Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.

Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential.

Renal dysfunction in allogeneic hematopoietic cell transplantation.

Transplantation of ex vivo expanded cord blood.

Human pulmonary chimerism after hematopoietic stem cell transplantation.

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

High-dose chemotherapy for breast cancer: is another look warranted?

Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy.

Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support.

Ex-vivo purging of hematopoietic progenitor cells.

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.

Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.

Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier.

Stem-cell transplantation for the treatment of advanced solid tumors.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.

Risk of transmission of herpesviruses through cord blood transplantation.

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies.

Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.

Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy.

Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.

Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?

Dendritic cell immunotherapy for the treatment of neoplastic disease.

Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.

Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.

Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.

A geometric approach to comparing treatments for rapidly fatal diseases.

Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.

Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.

Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.

Phase I trial of parathyroid hormone to facilitate stem cell mobilization.

Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer.

Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005.

Progress in dendritic cell immunotherapy: elucidating the enigma of Th-1 polarization.

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.

Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells.

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Cord blood stem cell therapy for acquired immune deficiency syndrome.

Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens.

De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination.

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.

Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells.

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.

Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU.

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

NK antibody therapy: KIR-ative intent.

High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.

piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.

Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.

Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.

Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Novel cord blood transplant therapies.

The 2011 education supplement on hematopoietic stem cell transplantation.

Unrelated donor transplantation for acute myelogenous leukemia in first remission.

Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation.

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement.

Mesenchymal stem cells in ex vivo cord blood expansion.

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.

HLA matching of CB: it's complicated.

Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

Steroid-Refractory Acute GVHD: Predictors and Outcomes.

High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later?

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas.

Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγnull (NSG) mice.

Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation.

Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.

Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.

Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique.

Cord blood graft engineering.

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome.

Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.

Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC.